A Look At GenScript Biotech (SEHK:1548) Valuation After New DNA Data Storage Collaboration With Mimulus

Genscript Biotech (SEHK:1548) is back in focus after announcing a multi year collaboration with Mimulus Corp to industrialize DNA based data storage, targeting scalable infrastructure and substantial cost efficiencies by 2030.

See our latest analysis for Genscript Biotech.

The collaboration headlines come as Genscript Biotech's share price, now at HK$12.62, shows mixed momentum, with a 13.8% 1 month share price return but a 12.42% decline over 3 months. The 1 year total shareholder return stands at 18.83%, compared with weaker multi year figures.

If this DNA based data storage story has caught your eye, it could be a good moment to widen your search and check out 121 healthcare AI stocks

So with Genscript Biotech trading at HK$12.62, mixed recent returns and a sizeable gap to analyst targets, is the market overlooking its DNA data storage potential or already pricing in the next leg of growth?

Most Popular Narrative: 32% Undervalued

With Genscript Biotech last closing at HK$12.62 against a widely followed fair value of HK$18.56, the prevailing narrative points to a sizeable valuation gap built on long term expansion and automation plans.

GenScript is capitalizing on the rapid expansion in biologics and cell/gene therapy demand by investing in automation, proprietary platforms, and global capacity, positioning the company for sustained revenue growth and market share gains as industry R&D cycles accelerate and outsourcing increases.

Read the complete narrative.

Curious what sits behind that growth story and valuation gap? The narrative leans heavily on a specific earnings trajectory, margin rebuild and future profit multiple that many investors would want to stress test for themselves.

Result: Fair Value of HK$18.56 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, investors still need to weigh risks such as rising global competition in gene synthesis and the heavy reliance on high growth subsidiaries such as Legend Biotech.

Find out about the key risks to this Genscript Biotech narrative.

Next Steps

Given the mix of optimism and caution in this story, it makes sense to look under the hood yourself and decide quickly where you stand using 3 key rewards

Looking for more investment ideas?

If Genscript Biotech is on your radar, do not stop there; broaden your watchlist now so you do not miss the next strong setup.

• Target potential mispricings by scanning for quality names trading below intrinsic value through the 234 high quality undervalued stocks.
• Strengthen your income stream by focusing on companies that combine higher yields with resilience using the 485 dividend fortresses.
• Prioritize resilience and capital protection by filtering for companies with lower risk profiles via the 301 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com